Alphamab Oncology (9966) Stock Overview

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for neoadjuvant treatment of HER2-positive breast cancer and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial for auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for advanced solid tumors with deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III clinical trials for biliary tract cancer. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody, which is in phase I clinical trial for the treatment of advanced solid tumors; and JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase Ia/Ib clinical trial for the treatment of advanced malignant solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.